US panel says toxicities of J&J's Yondelis outweigh benefits
This article was originally published in Scrip
Executive Summary
Centocor Ortho Biotech's (Johnson & Johnson) Yondelis (trabectedin) lacks a favourable risk/benefit profile to support use in relapsed ovarian cancer, the US FDA's oncologic drugs advisory committee said in a 14 to one vote.